Traders Purchase High Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Thursday. Stock investors acquired 44,506 call options on the company. This is an increase of 46% compared to the average volume of 30,418 call options.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific’s long-term growth prospects, pointing to opportunities in pulsed field ablation (PFA) and Watchman, while TD Cowen reiterated a Buy rating. TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
• Positive Sentiment: Unusually heavy call options activity suggests traders are positioning for a rebound, with call volume running well above normal.
• Positive Sentiment: Several analysts continue to view the recent selloff as a potential value opportunity, arguing the stock could recover if execution improves. Boston Scientific’s Fall From Penthouse To Doghouse Creates A Value Opportunity
• Neutral Sentiment: Jefferies lowered its price target to $67 from $100 but kept a Buy rating, implying the firm still sees meaningful upside from current levels. Jefferies lowers price target on Boston Scientific
• Negative Sentiment: Boston Scientific recently announced a nationwide recall of Orca single-use air/water and suction valves after reports of a malfunction, adding regulatory and operational risk. Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
• Negative Sentiment: Coverage around a targeted valve recall and questions about Watchman underscores rising scrutiny of Boston Scientific’s product execution and may be pressuring the shares. How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Robert W. Baird set a $70.00 target price on Boston Scientific in a research note on Thursday, May 28th. Leerink Partners cut their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Needham & Company LLC reissued a “buy” rating and issued a $77.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $83.36.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the company. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter valued at $26,000. Colonial Trust Co SC grew its position in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares in the last quarter. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth about $26,000. Finally, Bangor Savings Bank increased its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX traded down $0.17 during trading on Thursday, reaching $44.29. 10,436,440 shares of the company were exchanged, compared to its average volume of 17,745,578. Boston Scientific has a 12-month low of $43.89 and a 12-month high of $109.50. The company’s 50-day moving average is $53.67 and its two-hundred day moving average is $71.70. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market cap of $65.82 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.